HYDROCORTISONE ACETATE, A LONG-ACTING CORTICOIDvs. HYDROCORTISONE, A SHORT-ACTING CORTICOID

1959 ◽  
Vol 19 (12) ◽  
pp. 1682-1683
Author(s):  
ALBERT SEGALOFF
2013 ◽  
Vol 29 (10) ◽  
pp. 840-845 ◽  
Author(s):  
Andrea L. Rubinstein ◽  
Diane M. Carpenter ◽  
Jerome R. Minkoff

2021 ◽  
Author(s):  
Jorge Machado Alba

Introduction: Chronic obstructive pulmonary disease (COPD) affects approximately 174 million people worldwide.The objective was to determine the trends of the use of medications for COPD in a group of Colombian patients. Methods: This was a retrospective study on prescription patterns of bronchodilators and other medications used in COPD from a population database with follow-up at 12 and 24 months. Patients older than 18 years of age of any sex who had COPD between 2017 and 2019 were included. Sociodemographic variables, medications, treatment schedules for COPD, comorbidities, comedications, and the specialty of the prescriber were considered. Results: A total of 9,476 people with a diagnosis of COPD were evaluated. They had a mean age of 75.9 ± 10.7 years, 50.1% were men, and 86.8% were prescribed by a general practitioner. At the beginning of the follow-up, on average, they received 1.6 medications/patient, mainly short-acting antimuscarinics (3784; 39.9%), followed by short-acting β-agonists (2997, 31.6%) and inhaled corticosteroids (ICS) (2239, 23.6%), but 5083 (53.6%) patients received a long-acting bronchodilator. At the beginning of the follow-up, 645 (6.8%) patients were put on triple therapy with antimuscarinics, β-agonists, and ICS, and at 12 months, this rose to 1388 (20.6%). A total of 57.9% had comorbidities, most often hypertension (44.4%). Conclusions: This group of patients with COPD treated in Colombia frequently received short-acting bronchodilators and ICS, but a growing proportion are undergoing controlled therapy with long-acting bronchodilators, a situation that can improve the indicators of morbidity, exacerbations, and hospitalization.


1966 ◽  
Vol 4 (13) ◽  
pp. 52-52

This article stated that Actrapid and Nuso insulins can be mixed with protamine zinc insulin and other long-acting insulins. This is true, but we should have made it clear that in such a mixture the time-action characteristics of its components are likely to be altered, for some of the short-acting insulin is probably bound by the long-acting one.


2012 ◽  
Vol 76 (4) ◽  
pp. 833-842 ◽  
Author(s):  
Tohru Masuyama ◽  
Takeshi Tsujino ◽  
Hideki Origasa ◽  
Kazuhiro Yamamoto ◽  
Takashi Akasaka ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document